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Background: Because understanding of the inventory, connectivity and dynamics of the components
characterizing the process of coagulation is relatively mature, it has become an attractive target for physiochemical
modeling. Such models can potentially improve the design of therapeutics. The prothrombinase complex
(composed of the protease factor (F)Xa and its cofactor FVa) plays a central role in this network as the main
producer of thrombin, which catalyses both the activation of platelets and the conversion of fibrinogen to fibrin,
the main substances of a clot. A key negative feedback loop that prevents clot propagation beyond the site of
injury is the thrombin-dependent generation of activated protein C (APC), an enzyme that inactivates FVa, thus
neutralizing the prothrombinase complex. APC inactivation of FVa is complex, involving the production of partially
active intermediates and “protection” of FVa from APC by both FXa and prothrombin. An empirically validated
mathematical model of this process would be useful in advancing the predictive capacity of comprehensive
models of coagulation.
Results: A model of human APC inactivation of prothrombinase was constructed in a stepwise fashion by analyzing
time courses of FVa inactivation in empirical reaction systems with increasing number of interacting components
and generating corresponding model constructs of each reaction system. Reaction mechanisms, rate constants and
equilibrium constants informing these model constructs were initially derived from various research groups
reporting on APC inactivation of FVa in isolation, or in the presence of FXa or prothrombin. Model predictions were
assessed against empirical data measuring the appearance and disappearance of multiple FVa degradation
intermediates as well as prothrombinase activity changes, with plasma proteins derived from multiple preparations.
Our work integrates previously published findings and through the cooperative analysis of in vitro experiments and
mathematical constructs we are able to produce a final validated model that includes 24 chemical reactions and
interactions with 14 unique rate constants which describe the flux in concentrations of 24 species.
Conclusion: This study highlights the complexity of the inactivation process and provides a module of equations
describing the Protein C pathway that can be integrated into existing comprehensive mathematical models
describing tissue factor initiated coagulation.
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One of the critical events in blood coagulation is the conver-
sion of large amounts of the zymogen prothrombin to the
enzyme thrombin by the enzymatic complex prothrombinase.
The prothrombinase complex is formed by the non-covalent
interaction between the enzyme factor Xa (FXa) and the
non-enzymatic cofactor factor Va (FVa) on a phospholipid
surface in the presence of calcium [1-3]. The procofactor,
factor V, is activated by thrombin to generate a calcium-
associated two chain molecule, composed of a heavy chain
(FVaHC) and light chain (FVaLC) (Figure 1) [4,5]. The
prothrombinase complex increases thrombin generation
over FXa alone by 5 orders of magnitude [2]. The explo-
sive burst in prothrombin conversion is essential to rap-
idly form a stable fibrin clot in response to a vascular
injury. The fibrin clot is formed when thrombin cleaves
fibrinogen to form an insoluble polymer network [6,7].
This fibrin network becomes cross-linked and stabilized
by factor XIIIa which also traps platelets and red blood
cells sealing the wound [7-9].
It is critical that once a procoagulant response to vascu-
lar injury has been initiated that an appropriate anticoagu-
lant response is concurrently mounted. As such, the
components of the prothrombinase complex are targets of
multiple regulatory mechanisms to terminate the produc-
tion of thrombin. First, FXa availability is regulated by for-
mation of inhibition complexes with antithrombin (AT),
α1-antitrypsin, and tissue factor pathway inhibitor (TFPI)
[10,11]. The cofactor, FVa, is a target for degradation by
activated protein C (APC). APC, a serine protease derived
from its plasma precursor protein C (PC) in a thrombin
dependent process [12], plays a critical role in inactivating
the non-enzymatic cofactor components of both the
prothrombinase and the intrinsic tenase complexes, fac-
tors Va and VIIIa, respectively [13-15]. Additional key
components of the PC pathway include: thrombomodulin
and endothelial protein C receptor (EPCR) which contri-
bute to APC formation [16]; protein S which functions as
a cofactor enhancing APC efficacy [17]; and protein C in-
hibitor, a suppressor of APC formation [18,19].
An increased risk of thrombotic disease has been asso-
ciated with partial deficiencies or loss of function muta-
tions in the PC pathway, including deficiencies in PC, its
cofactor protein S, or proteins involved in the activation
of PC [20]. The most prevalent defect in the PC pathway
is a result of a genetic mutation in FV that renders the
cofactor resistant to APC inactivation [21]. This resis-
tance to APC was first characterized by Dahlbäck and
coworkers [21] and derives from a mutation at one of
the APC inactivation sites (Arg506!Gln506) on FV/FVa
rendering it resistant to APC cleavage [22].
APC catalyzed inactivation of FVa cofactor activity
is a complex, membrane dependent process involving
cleavage at multiple sites in the FVaHC, the generation oftransient species with partial cofactor activity, and the
ultimate disassociation of a fragment of the FVaHC from
the molecule rendering it catalytically inactive. APC
interacts with FVa or partially proteolyzed FVa species
through their light chains to form enzyme•substrate
complexes [23-25]. Additional studies have identified
other regions of interaction, including the proteolytic
target residues and the surrounding regions, in the FVa
heavy chain involved in the enzyme•substrate complex
formation [26-28]. Three arginine residues are targeted
in human APC•FVa complexes: Arg306, Arg506, and
Arg679 [15,29]. A number of studies have defined the ac-
tivities of the partially proteolyzed FVa species [30,31].
Cleavage at either Arg306 or Arg506 results in cofactor
species, FVai
306 and FVai
506, respectively, with reduced
but similar cofactor activity in the prothrombinase com-
plex (Figure 1) [30,31]. Cleavage at Arg306 has been
shown to be essential for full loss of cofactor activity
[32]. The significance of the cleavage at Arg679 remains
undetermined. The final inactive cofactor, FVai, is a two
chain molecule composed of the FVaLC and FVa1-306
fragment (Figure 1) [32]. The inactive cofactor binds
APC with the same affinity as the intact cofactor [23,33],
suggesting a potential role of product inhibition in regu-
lating APC efficacy [33].
The complexity of this process led Hockin and coworkers
to construct an ordinary differential equation based
description of the network of reactions characterizing the
process of bovine APC inactivation of bovine FVa using
rate constants gleaned from studies with bovine, human
and recombinant human proteins [33]. Empirical studies
from a number of laboratories detailing APC inactivation of
FVa have shown the cleavage at Arg506 preceding that at
Arg306, with these data initially (often) being interpreted as
indicating a sequential or ordered kinetic mechanism [15].
However, based on their mathematical modeling, Hockin
et al. [33], concluded that the reaction pathway was better
described as a random order cleavage process for Arg306
and Arg505 (Arg506 in human FVa) in which each of the
cleavages is independent of the other, but occurs at different
rates (Figure 2), and where full loss of cofactor activity
requires disassociation of the fragment of the FVaHC down-
stream from the Arg306 cleavage [32,33].
Numerous studies examining how components like FXa,
prothrombin and protein S modulate APC inactivation of
FVa have been reported [14,34-40]. These studies routinely
employ approaches like progress curve analysis based on
curve fitting to compare initial rates, or natural and recom-
binant cleavage site mutants to detail mechanistic features.
To date, however, an integrated approach, one combining
the use of physicochemical model construction based on
prior research and model verification via construction of
corresponding reaction systems using purified proteins,
has not been extended to understand APC regulation of
Figure 1 (See legend on next page.)
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Figure 1 Schematic Representation of Factor Va and the Mechanism of the APC-Generated Partially Proteolyzed Species. Human factor
Va (FVa), consisting of the non-covalently associated 105 kDa heavy chain (FVaHC) and 74/72 kDa light chain (two carbohydrate variants) (FVaLC),
has maximal cofactor activity in the prothrombinase complex. FVa contains three APC cleavage sites: Arg306, Arg506, and Arg679; cleavage at Arg679
plays a minimal role in altering cofactor activity and so will not be considered further. APC cleaves FVa in a random, non-sequential manner at





proteolyzed by APC at Arg506 or Arg306, respectively, to generate the FVai
306/506 species. Prothrombinase activity is possible even when the FVaHC
has been proteolyzed at both sites as long as the heavy chain fragments remain associated with each other and the FVaLC. The partially active
FVai
306 and FVai
306/506 species lose full activity with the spontaneous dissociation of either the FVa307-679/709 or FVa307-506• FVa507-679/709 fragments,
respectively. Fragments shaded in black are recognized by the monoclonal antibody (αHFV#17) and their apparent (SDS-PAGE) molecular weights
are indicated.
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this study we build on the prior studies modeling APC
inactivation of FVa [33] by incorporating the presence
of additional components of the prothrombinase complex
(FXa and prothrombin) to construct an empirically vali-
dated mathematical model. To test model constructs, a
step-wise approach to increasing the number of compo-
nents was used. Experiments were replicated multiple
times with different preparations of proteins in order to
generate robust data sets that included estimates of meas-
urement error. At each level of complexity, we empirically
monitored multiple analytes, including starting reactants,
intermediates and final products to provide multiple points
of comparison to evaluate each model’s performance.
Results and Discussion
APC Inactivation of Factor Va
Empirical Analyses
The inactivation of FVa (20 nM) was monitored at two
APC concentrations (0.5 and 2.0 nM) in the presence of
excess PC:PS vesicles (20 μM). The lower concentration of
APC was used to initiate a slow inactivation reaction that
would enable multiple time points to monitor the se-
quence of proteolytic events and the residual cofactor ac-
tivity (as measured by a one stage clotting assay). In
studies with 0.5 nM APC, within one minute there was a
50 % loss in cofactor activity (Figure 3, Panel A, black cir-
cles) which continued in a monophasic decay. According
to previous studies, measurement of FVa cofactor activityFigure 2 Mechanism of the APC Inactivation of Factor Va. Random no
Hockin et al. [33] renumbered with human FVa cleavages.as measured in clotting assays is sensitive to APC cleavage
of Arg506 [41].
Western blot analyses (representative blot in Figure 3,
Panel B) monitoring the disappearance of intact FVaHC
(residues 1–709) display the rapid proteolysis of FVa
heavy chain proteolyzed at either site within the first
or third minutes with 2.0 or 0.5 nM APC, respectively
(Figure 3, Panel C, red and black circles, respectively).
These results were each fit to monophasic exponential
decays (fit not shown), and the initial slope of the
fitted curve was determined after normalizing the
densitometry to the maximal value (RMV). At 0.5 nM
APC, the initial rate of disappearance of the heavy
chain was 200 pM/s (based on 20 nM starting concen-
tration); at 2.0 nM APC, the rate of disappearance was
nearly three-fold faster (558 pM/s). The disappearance
of the heavy chain is initially concurrent with accumu-
lation of the FVa1-506 fragment (Figure 3, Panel D).
The generation of the FVa1-506 fragment reaches a
maximum within 30 sec (2.0 nM APC) or 90 sec (0.5
nM APC) (Figure 3, Panel D, red and black circles, re-
spectively). At this point most of the FVaHC has been
proteolyzed primarily at Arg506, and the secondary
cleavage at Arg306 in the FVa1-506 species becomes the
dominant proteolytic event. Analysis of the appearance
of the inactivation fragment FVa307-506 (resulting from
cleavage at both Arg306 and Arg506, Figure 3, Panel E),
indicates that as the FVa1-506 fragment is approaching
its maximum level it is being further proteolyzed ton-ordered APC cleavage mechanism of bovine FVa proposed by
Figure 3 (See legend on next page.)
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Figure 3 Inactivation of Factor Va by Activated Protein C. Empirical: FVa (20 nM, Panels A-E) or FVai
506 (20 nM, Panel F) was incubated with
PC:PS vesicles (20 μM) and APC (0.5 or 2.0 nM) at 37°C. All data points are presented as averages ± S.D. of 4–6 experiments for each time point.
(A) Time course of APC (0.5 nM) inactivation of FVa. Cofactor activity is presented relative to activity present at zero point (black circles). (B)
Representative Western blot of time course of APC (2.0 nM) inactivation of FVa. (C) Densitometric analyses of the disappearance of FVaHC at 0.5 or
2.0 nM APC (black and red circles, respectively). (D) Densitometric analyses of the time course of FVa1-506 at 0.5 or 2.0 nM APC (black and red
circles, respectively). (E) Densitometric analyses of the time course of FVa307-506 at 0.5 or 2.0 nM APC (black and red circles, respectively). (F)
Densitometric analyses of the inactivation fragment FVa307-506 generated during the APC (0.5nM) inactivation of FVai
506 (open circles). Inset
displays a representative Western blot. Mathematical: Mathematically derived time courses of FVa inactivation by APC (0.5 nM - black lines and 2.0
nM - red lines) for the corresponding analytes are also presented in Panels A and C-F. Simulated time courses were generated using two sets of
rate constants: Hockin et al. [33] – dashed lines; and current study – solid lines.
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of proteolysis at Arg306, FVai
506 was used as the start-
ing material in inactivation studies with 0.5 nM APC
(Figure 3, Panel F, open circles). This membrane bound
partially proteolyzed species has already lost most of its
cofactor activity in a clotting assay [30,31,33]. Tracking
of the final inactivation fragment, FVa307-506, by Western
blotting reveals a monophasic accumulation of this
fragment (fit not shown) (Figure 3, Panel F).
Mathematical Simulations
Using the non-sequential reaction mechanism proposed by
Hockin et al. (Table 1, Figure 2) [33] and kinetic constants
used to describe their bovine system of proteins, in silico
simulations of APC inactivation of FVa were performed
and predicted time courses for various FVa inactivation
species compared to the empirical data presented in
Figure 3. Mathematical simulations show good correlation
with empirical measurements of FVa cofactor activity and
the densitometric analysis of FVaHC (Figure 3, Panel A and
C, dashed lines vs. filled circles, respectively). Hockin et al.
reported a good fit using this model between simulated andTable 1 Equations describing APC inactivation of factor Va
Eqn Chemical Expressiona
1 APC+ FVa 2-1!APC•FVa
2 APC•FVa −3!APC+ FVai506










306 -5! FVa1-306•FVaLC + FVa307-679/709
9 FVai
306/506 -5! FVa1-306•FVaLC + FVa307-506 + FVa507-679/709
10 APC+ FVa1-306•FVaLC 2-1!APC• FVa1-306•FVaLC
a For equilibrium expressions denoted by 2-1!, the first number listed describes
b Rate constant used for mathematical simulations as determined by inactivation st
c Rate constant used for mathematical simulations, as determined by inactivation st
constant will be used in all subsequent mathematical simulations.empirical time courses of APC catalyzed changes in cofac-
tor activity in the bovine system [33]. The present study’s
correlation between clotting assay measurements, in silico
FVa cofactor activity, and densitometric analysis of FVaHC
are consistent with the findings of earlier studies that FVa
cofactor activity is based on the amount of intact FVaHC
present [41].
However, the predicted generation and disappearance of
the FVa1-506 fragment are significantly delayed compared to
the empirical data for this inactivation fragment (Figure 3,
Panel D, black dashed line vs. black circles). At 0.5 nM
APC, the simulation predicts that this fragment will reach a
maximum at 3.4 min before slowly disappearing, with 30 %
still remaining after 20 min; the empirical experiments
show the peak level reached at 1.5 min with only 9 %
remaining after 20 min (Figure 3, Panel D, black dashed
line vs. black circles). The mathematical simulation fared
better with 2.0 nM APC (Figure 3, Panel D, red dashed line
vs. red circles) with respect to the timing of peak accumula-
tion, however failed to recapitulate the rapid clearance of
this fragment. Mathematical simulations of FVa307-506 using
the Hockin et al. [33] rate constants resulted in ankoff kon kcat kdis
(s-1) (M-1 s-1) (s-1) (s-1)




0.7 1 x 108






0.7 1 x 108
the reverse reaction given in the koff column.
udies with bovine FVa and bovine APC in Hockin et al. [33].
udies with human FVa and human APC in this study, is 0.192 s-1. This new rate
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compared to empirical data (Figure 3, Panel E, dashed lines
vs. circles).
Though the bovine based Hockin et al. [33] rate con-
stants clearly captured the disappearance of FVaHC as mea-
sured through activity and fragment analysis, they did not
accurately predict the presentation of either the FVa1-506 or
FVa307-506 fragments in the human system. The rapid
clearance of the FVa1-506 fragment and faster appearance
of the smaller FVa307-506 fragment led us to speculate that
their model rate constant for the cleavage at Arg306 was
not appropriate for the human system of proteins. From a
comparison of the empirical data to the initial in silico
simulation we estimated that the rate of cleavage occurring
at Arg306 was three times faster than the model predic-
tions. To account for this the rate constant (Figure 2, k4;
Table 1, Eqns 3 and 6) in the mathematical model was
adjusted from 0.064 s-1 to 0.192 s-1 and simulations rerun
for all analytes (Figure 3, solid lines). As expected the
simulated predictions for FVa cofactor activity and FVaHC
were minimally altered by this change and continued to
correlate well with their respective empirical measures
(Figure 3, Panels A and C, solid lines vs. filled circles). The
adjusted rate constant significantly altered the in silico pre-
dictions for both smaller FVa inactivation fragments
(Figure 3, Panels D and E, solid lines vs. dashed lines)
yielding a better fit with empirical results. The revised
model using the adjusted kinetic rate was extended to
experiments conducted with FVai
506 and the predicted time
courses for the two models compared to the empirical
results (Figure 3, Panel F, solid lines and dashed lines vs.
open circles). As can be seen in all simulations, those using
the published bovine model values (Figure 3, dashed lines)
resulted in a poorer fit [33]. The rate constant for cleavage
at Arg306, k4, was adjusted to 0.192 s
-1 for all subsequent
studies.
Our empirically driven adjustment to k4 results in a
second order rate constant for the overall process of clea-
vage at Arg306 of 2.74 x 107 M-1 s-1. Previously published
second order rate constants for the APC cleavage at Arg306
in human FVa (1.55 x 106 M-1 s-1 [42], 1.7 x 106 M-1 s-1
[31], and 2.5 x 106 M-1 s-1 [41]) are an order of magnitude
lower than our currently derived estimate and lower than
that used by Hockin et al. (9.1 x 106 M-1 s-1 [33]) to describe
the bovine system.
Studies using human proteins on APC inactivation of
FVa reported second order rate constants for the cleavage
at Arg506 ranging from 3.0-4.3 x 107 M-1 s-1 [31,41]; a
more recent study by Nicolaes et al. [42] has reported the
second order rate constant to be 1.17 x 108 M-1 s-1. This
value is quite similar to the value (1.42 x 108 M-1 s-1) used
in the current study.
An alternative approach to fitting these data sets
would have been to use an optimization method inwhich all rate constants may be simultaneously adjusted
to generate a best fit to all the experimental data. Failure
of model predictions to fit the empirical data can stem
from the collective effect of small errors in the rate con-
stants used. It is not uncommon for laboratories to report
2–3 fold differences in rate constants of biochemical reac-
tions and interactions measured in vitro. These ranges are
accepted because the findings would fall within the mar-
gin of error expected for slightly variable experiments
conducted in different laboratories, or for different techni-
ques used to measure a rate constant. Such variation can
have significant effects on model outputs [43]. However,
lack of fit can arise from a fundamental mistake or omit-
ted interaction in the reaction description. Therefore, we
have not taken this approach as we developed this model.
APC Inactivation of Factor Va: Effect of Factor Xa Under
Non-saturating Conditions
It has been widely reported that FXa shields FVa from de-
gradation by APC through its reversible association in the
prothrombinase (FXa•FVa) complex [34-38,44]. The me-
chanistic basis of this protection has been conceptualized
as a mutually exclusive competition for association with
membrane bound FVa, so that when FVa is associated with
FXa it is not a substrate for APC [35], at least at the Arg506
site [37]. In order to develop a model description that can
predict the extent of the protective effect exerted by FXa
against APC proteolysis of FVa over a range of reactant
concentrations, empirical experiments were performed at
saturating and non-saturating concentrations of FXa.
Empirical Analyses
In the first set of experiments, prothrombinase was pre-
formed under non-saturating concentrations with FVa in
excess (0.2 nM FVa and 0.1 nM FXa) on 20 μM PC:PS
vesicles. Under these conditions, if the KD = 0.5 nM for
the (FXa•FVa) complex (estimate based on previous stud-
ies [45]), only 13 % of the FVa would be expected to be
bound to FXa. Inactivation reactions were initiated with 0,
0.5, or 2.0 nM APC. For these experiments, the amount of
thrombin generated in the 0 nM APC control was set at
100 % prothrombinase activity, with thrombin generation
levels represented relative to the prothrombinase activity
in the 0 nM APC control. The loss of prothrombinase ac-
tivity following the addition of APC at either concentra-
tion (Figure 4, Panel A, filled circles) appeared to follow a
monophasic decay (fits not shown).
Mathematical Simulations
To simulate this experiment, six additional equations
were required (Table 2, Eqns 11–16). Of these, four
equations describe the formation of a prothrombinase
complex between FXa and FVa (FXa•FVa) or any of the
three partially proteolyzed FVa species (FXa•FVai
506,
Figure 4 Effect of Factor Xa on Activated Protein C Inactivation
of Factor Va. Empircal time courses of FVa inactivation measured
by activity analysis (Panels A and B) or by monitoring proteolytic
cleavages (Panel C) are presented along with corresponding
simulated time courses. All data points are presented as
averages ± S.D. of 4–6 experiments. (A,B) Empirical time courses of
APC (0.5 nM – black circles; 2.0 nM – red circles) inactivation of
preformed prothrombinase (200 pM FVa and 100 pM FXa).
Corresponding simulated time courses for 0.5 nM (black) or 2.0 nM
(red) APC are presented with three potential KD values for the
formation of the prothrombinase complex (100 pM – dotted lines;
500 pM – dashed lines; 750 pM – solid line): in Panel A each
equilibrium process was described using a kon (4.0 x 10
8 M-1 s-1) and
adjusting the koff constant; in Panel B each equilibrium process was
described using a kon (1.5 x 10
8 M-1 s-1) and adjusting the koff
constant. (C) Empirical time course of 2.0 nM APC inactivation of
preformed prothrombinase (20 nM FVa and 30 nM FXa*) anaylzed by
Western blotting. FVaHC densitometric data are expressed as relative
to its value at time 0 (red circles). Corresponding simulated time
courses for 2.0 nM (red) APC are presented using three potential KD
values for the formation of the prothrombinase complex with each
equilibrium process described by using a kon (1.5 x 10
8 M-1 s-1) and
adjusting the koff constant (100 pM – dotted lines; 500 pM – dashed
lines; 750 pM – solid line).
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306, and FXa•FVai
306/506) using a KD twice that de-
scribing the complex formed with intact FVa (FXa•FVa)
(based on previous studies [32]). Several empirical studies
using plasma derived FVa and recombinant FVa mutants
have demonstrated that FVai
506 and FVai
306 can complex
with FXa and form a productive enzyme complex [31,32,41].
Two additional equations allow for the dissociation of heavy




Our initial mathematical simulations were carried out
utilizing a KD of 0.5 nM [45], resulting in an initial con-
centration of 26 pM for prothrombinase, with off and on
rates of 0.2 s-1 and 4.0 x 108 M-1 s-1, respectively (Table 2,
Eqn 11) [46,47]. The mathematical predictions for the
loss of prothrombinase activity in the presence of either
0.5 or 2.0 nM APC showed an approximately 2-fold fas-
ter loss in prothrombinase activity than observed in the
empirical experiments (Figure 4, Panel A, dashed lines
vs. filled circles).
To generate a better fit to the empirical data we first
examined the dissociation constant of FXa and FVa on
PC:PS vesicles, which by literature reports varies from as
low as 83 pM [31] to as high as 1 nM [48]. Simulations
to test the wide range of reported KD values were first
conducted by altering the koff rate constants for the pro-
thrombinase complex, while maintaining the same kon
rate constant of 4.0 x 108 M-1 s-1. For each KD value
tested, the starting concentrations of free and bound
species (FVa, FXa, and FXa•FVa) were recalculated and
used as the initial conditions for a mathematical simula-
tion. An adjustment made to the off rate for the pro-
thrombinase complex resulting in a KD of 0.1 nM (58.8
Table 2 Equations describing interactions between intact and partially proteolyzed factor Va with factor Xa and
prothrombin
Eqn Chemical Expression koff kon kdis
(s-1) (M-1 s-1) (s-1)
11 FXa + FVa 7-6! FXa•FVa 0.2 a 0.075 b 4 x 108 a
1.5 x 108 b
12 FXa + FVai
506 8-6! FXa•FVai506 0.4 c 4 x 108 c
0.15 b 1.5 x 108 b
13 FXa + FVai
306 8-6! FXa•FVai306 0.4 c 4 x 108 c
0.15 b 1.5 x 108 b
14 FXa + FVai
306/506 8-6! FXa•FVai306/506 0.4 c 4 x 108 c
0.15 b 1.5 x 108 b
15 FXa•FVai
306 -9! FXa + FVa1-306•FVaLC + FVa307-679/709 0.0035
16 FXa•FVai
306/506 -9! FXa + FVa1-306•FVaLC + FVa307-506 + FVa507-679/709 0.0035
17 FVa + PT 11-10! FVa•PT 70d 1 x 108
a Values from previously published studies for mathematical simulations [32,46].
b Values identified in the current study for mathematical simulations and carried forward through all subsequent mathematical simulations.
c Values are based on relative findings from previously published studies for mathematical simulations [32].
d Initial estimate for FVa•PT complex from Tran et al. [39].
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diction that more closely represented the empirical
results seen with both 0.5 and 2.0 nM APC (Figure 4,
Panel A, black and red, respectively, dotted lines vs filled
circles).
In addition to altering the koff rate constant while
maintaining a kon rate constant to reach a desired
overall KD, changes to both isolated rate constants
were explored as a potential solution. One alternative
that we explored was adjusting the kon rate constant
to 1.5 x 108 M-1 s-1 and setting the koff rate constant
to values that yielded the same set of KD values.
Figure 4, Panel B presents these model results at 0.5
and 2.0 nM APC (black and red, respectively) for KD's
of 0.5 nM (dashed lines) and 0.1 nM (dotted lines) for
prothrombinase assembly. In contrast to simulations
based with a kon value of 4.0 x 10
8 M-1 s-1 this analysis
indicates that a KD of 0.5 nM yields a better fit to the
data.
These results highlight an important feature of dy-
namic systems like this one: the magnitude of the
observed protective effect may depend not only on the
concentrations of the three protein components and the
KD's characterizing their interactions, but also on the
rate constants defining the competing KD's.
APC Inactivation of Factor Va: Effect of Factor Xa Under
Saturating Conditions
The previous analysis under non-saturating conditions
indicates that either a dissociation constant of 0.1 nM or
0.5 nM for the prothrombinase complex can recapitulate
our empirical data depending on the values assigned to
kon and koff. From the point of view of empiricallymeasuring kon and koff values the differences in these
assigned values (e.g. ~2.5 fold between 1.5 or 4.0 x
108 M-1 s-1) are small and within the margin of error for
this type of analysis. In order to further explore which
dissociation constant and set of rate constants is appro-
priate for the empirical data, we tested APC inactivation
of FVa under saturating conditions with FXa present in
excess (Figure 4, Panel C and Figure 5).
Empirical Analyses
Figure 5 presents empirical experiments in which pre-
formed prothrombinase (20 nM FVa and 30 nM active
site blocked FXa (FXa*)) was treated with 2.0 nM APC
and time courses of FVaHC and its APC-derived frag-
ments FVa1-506, FVa307-679/709 and FVa307-506 visualized
by Western blotting (Figure 5, Panel A, inset). Under
these conditions, 95 % to 99 % of the FVa is bound to
FXa* prior to addition of APC given KD values in the
range of 0.5 nM to 0.1 nM, respectively. The selection of
20 nM FVa reflected the fact that in closed model
systems of TF-initiated coagulation, levels of FVa reach
20 nM [49] and the practical requirement for a concen-
tration suitable for Western blot analysis. Active site
blocked FXa was used to prevent FXa proteolysis of FVa
[50].
Reactions where the FVa population is highly associated
with FXa* showed 70 % of FVaHC remained after 1 minute
(Figure 4, Panel C and Figure 5, Panel A, red circles) com-
pared to~10 % without FXa* (Figure 3, Panel C, red
circles). Comparison of initial rates showed a greater than
7-fold reduction in the initial rate of 2.0 nM APC proteo-
lysis of FVa due to its FXa association (77 pM/s vs. 558
pM/s). Consistent with this overall suppression of heavy
Figure 5 (See legend on next page.)
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Figure 5 APC Inactivation of FVa in the Presence of a Saturating Concentration of FXa. Empirical: FVa (20 nM, Panels A-D) or FVai
506 (20 nM,
Panel E and F) was pre-incubated with active site blocked FXa* (30 nM) at 37°C. The reaction was then initiated with 2.0 nM APC. The inactivation
of FVa was monitored by densitometry for the following fragments: FVaHC (Panel A), FVa1-506 (B), FVa307-679/709 (C) and FVa307-506 (D) and the
inactivation of FVai
506 was monitored by following FVa1-506 (E) and FVa307-506 (F). All data points with FVa are presented as averages ± S.D. of 4–6
experiments and data points with FVai
506 are presented as averages ± S.D. of 2 experiments. Mathematical: Simulated time courses in which the
model description does not allow APC proteolysis of the FXa•FVai
506 complex (dotted line) or allows the cleavage by APC at Arg306 in the
FXa•FVai
506 complex with rate constants of 2.5 x 106 M-1 s-1 (dashed line), 5.0 x 106 M-1 s-1 (solid line), or 9.1 x 106 M-1 s-1 (dash with dotted line).
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slower in the presence of FXa*, reaching a maximum in
2 min vs ~30 s in its absence (Figure 5, Panel B vs.
Figure 3, Panel D, red circles). Its clearance was also sup-
pressed, taking~4 min to decline to 50 % of its maximum
as opposed to ~1 min without FXa* (Figure 5, Panel B vs.
Figure 3, Panel D, red circles).
In contrast to APC inactivation studies conducted in the
absence of FXa*, visual inspection of Western blot images
(Figure 5, Panel A, inset) reveal the accumulation of the
FVa307-679/709 fragment leading to more reliable quantitative
densitometric analysis of this fragment (Figure 5, Panel C,
red circles). Generation of this fragment reaches 50 % of its
maximal level by 1 minute, and remains at elevated levels
above 70 % of maximal level after 2 minutes (Figure 5,
Panel C, red circles). Generation of the FVa307-506 fragment
reaches 50 % of maximal value after 3 minutes (Figure 5,
Panel D, red circles).
Mathematical Simulations
Initial prothrombinase concentrations given the condi-
tion of pre-incubating 20 nM FVa and 30 nM FXa* were
calculated to be 19.1 nM or 19.8 nM using KD values of
either 0.5 nM or 0.1 nM, respectively. A range of kon
and koff rate constants for each KD were tested by vary-
ing kon values between 1 and 4.0 x 10
8 M-1 s-1. Time
courses of the inactivation of FVa by 2.0 nM APC were
produced. The results of this in silico study indicated
that the disappearance of FVaHC was dependent on the
resultant KD value and independent of the combination
of kon and koff rate constants used to generate the KD
values of 0.1 or 0.5 nM (data not shown). Assuming the
KD for prothrombinase is 0.1 nM and the kon is either
1.5 x 108 M-1 s-1 or 4.0 x 108 M-1 s-1, the model predicts
that after 6 min 25 % of the FVaHC is proteolyzed
(Figure 4, Panel C, red dotted line), in contrast to the
empirical results showing ~82 % of FVaHC proteolyzed
at 6 minutes (Figure 4, Panel C, red circles). Model
simulations with KD values of 0.5 nM, 0.75 nM or 1.0
nM resulted in FVaHC levels decreasing after 6 min by
75 % (Figure 4, Panel C, red dashed line), 83 % (Figure 4,
Panel C, red solid line), or 87 % (data not shown), re-
spectively. From the mathematical simulations, the ini-
tial rates of FVaHC proteolysis were 22 pM/s, 86 pM/s,
and 122 pM/s for KD’s of 0.1 nM, 0.5 nM, and 0.75 nM,respectively, compared to the empirically derived rate of
FVaHC proteolysis of 78 pM/s. Overall these compari-
sons support our eliminating 0.1 nM as the KD for the
prothrombinase complex.
While the mathematical model is able to recapitulate the
overall combined initial cleavages of FVaHC (Figure 5, Panel
A, dotted line vs. filled circles), there is a mixed success for
the predictions of the inactivation fragments (Figure 5,
Panels B-D, dotted line vs. filled circles). Specifically, the
mathematical model captures the rapid accumulation of
the FVa307-679/709 fragment (Figure 5, Panel C, dotted line),
but does not capture the clearance of the FVa1-506 fragment
(Figure 5, Panel B, dotted line) or the generation of the
FVa307-506 fragment (Figure 5, Panel D). The same lack of
fit for the proteolysis of this fragment is observed when
FVai
506 is the starting substrate (Figure 5, Panels E and F,
dotted line vs. filled circles).
In the mathematical model as constructed APC prote-
olysis at any site is permitted only with FVa species not
bound to FXa (or FXa*). The more rapid clearance of
FVa1-506 observed empirically suggests two possible pro-
blems with the model construct: 1) the binding affinity
between FVai
506 and FXa is weaker than the model value
of 1 nM based on studies with bovine FVa [32] or 2)
APC can cleave at Arg306 when the FVai
506 species is
bound to FXa. Previous studies with recombinant
human proteins have reported KD values ranging from
~3.9 nM [31] to ~1.35 nM [51]. To evaluate the likeli-
hood that a weaker binding affinity was the culprit,
mathematical simulations were conducted where the KD
for the FXa•FVai
506 complex was varied; to fit the empi-
rical data the KD for this complex would have to be
greater than 10 nM (data not shown) and as such this
adjustment was discarded as a viable option.
The alternative explanation for the empirical data pre-
senting the clearance of the FVa1-506 fragment is that when
bound to FXa, the FVai
506 species is susceptible to APC
cleavage at Arg306. To explore this hypothesis, an additional
reaction was added to the mathematical construct: APC
cleaving (FXa•FVai
506) at Arg306. To establish whether there
was a value for this rate constant that would improve the
fit, simulations varying its value were run using the model
value (2.7 X 107 M-1 s-1) for the cleavage of Arg306 in free
FVa as a point of reference. Representative examples are
presented in Figure 5. The mathematical analysis suggests
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506) is a target for APC, the
magnitude of the rate constant regulating the event is ~10
to 20 % that for free FVa.
Structural Analysis
Analysis of the proposed structural models of the
prothrombinase complex allows for the possibility that
Arg306 is susceptible to APC in the FXa•FVai
506 complex
[52-54]. The prothrombinase complex models differ in the
orientation of FXa relative to FVa, and the binding interface
between enzyme and cofactor. What is consistent between
the three models is that Arg506 in FVa is occluded by the
binding of FXa, rendering this site inaccessible to APC
cleavage (Figure 6). Additionally Arg306 is surface exposed
and not masked by FXa in any of the models. As such, the
structural models suggest that this arginine site could be
accessible to APC cleavage even when FVa or FVai species
are complexed to FXa. However, mathematical simulations
allowing the cleavage to occur in FVa while bound to FXa
overestimate both the rate of FVaHC disappearance and the
rate of generation of FVa307-679/709 fragment observed em-
pirically (data not shown). The data was best fit by mode-
ling only the FXa•FVai
506 complex as susceptible to cleavage
at Arg306. Thus the kinetic and structural modeling in con-
cert with the empirical data suggests two effects: binding
of FVa to FXa blocks both cleavage at Arg306 and Arg506Figure 6 Structural Simulations of the Prothrombinase Complex. Top a
complex from three separate groups: Left, [52], Center [53], Right [54]. In the
on previously solved crystal structures [PDB ID: 1XKA] [55]. In all three simu
bovine inactivated FVai (FVa
1-306•FVaLC) solved by Adams et al. [PDB ID: 1SD
presented in green, and the hypothetical structure of FVa307-709, which is b
ceruloplasmin [PDB ID: 1KCW] [57], is presented in orange. The Arg306 resid
residue in black and encircled by a black circle; dashed circles indicate the
presented view point.despite the unmasked surface exposure of Arg306; and
that binding of FXa to FVai
506 improves the geometry at
Arg306 rendering the site vulnerable to APC.
APC Inactivation of Factor Va: Effect of Prothrombin
In addition to the protection afforded to FVa by FXa in
the prothrombinase complex, the substrate of the com-
plex, prothrombin (PT), has also been shown to inhibit
APC inactivation of FVa [39,40,58]. Guinto and Esmon
reported that prothrombin protects the intact FVa mo-
lecule by competing with APC for binding to FVa [58];
more recent studies have reported a KD of between
500–700 nM for FVa and prothrombin [39,40].
Empirical Analyses
In order to quantify the degree to which prothrombin
protects FVa from APC, reactions were carried out at
physiological concentrations of FVa (20 nM) and pro-
thrombin (1.4 μM) on phospholipid vesicles (20 μM).
Reactions were triggered with APC (2.0 or 20.0 nM) and
aliquots removed for Western blot analysis (representa-
tive blot in inset of Figure 7, Panel A). The presence of
prothrombin in the system clearly protected FVa from
APC inactivation by 2.0 nM APC. After 20 minutes
35 % of FVHC remained intact (Figure 7, Panel A, red
circles), compared to less than 5 % intact within 6nd front views of the structural simulations of the prothrombinase
three models the FXa structures (presented in light blue) are based
lations, the FVa domain orientation is based on the crystal structure of
D] [56]. The FVa1-306 fragment is presented in purple, the FVaLC is
ased on the homology comparisons to the structure of human
ue is marked in red and encircled by a red circle and with the Arg506
residue in question is completely masked by a structure from the
Figure 7 Effect of Prothrombin on the APC Inactivation of FVa. Empirical: FVa (20 nM) was pre-incubated with prothrombin (1.4 μM) at 37°C.
The reaction was initiated with 2.0 nM (red circles) or 20.0 nM (blue circles) APC. A representative Western blot is shown in the Panel A inset.
Data are normalized densitometric values for the following fragments: FVaHC (Panel A), FVa1-506 (B), FVa307-679/709 (C) and FVa307-506 (D). Data points
are the averages ± S.D. of either 4 or 3 experiments for inactivation studies conducted with either 2.0 or 20.0 nM APC, respectively. Mathematical:
Simulated time courses (2.0 nM APC – red lines; 20.0 nM APC – blue lines) were generated under two modeling conditions: 1) The assumption of
unlimited binding sites for all species and a KD of 700 nM for FVa•PT complex (dash and dotted lines) [39]; and 2) The assumption of limited
binding sites, thus reducing the effective APC concentration, with hypothetical KD values for the FVa•PT complex of 0 nM (dotted line), 500 nM
(dashed line), or 700 nM (solid line) are shown.
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C, red circles). The initial rate of proteolysis of the heavy
chain was reduced ~ 16-fold (34 pM/s vs. 558 pM/s).
The formation of the FVa1-506 fragment (Figure 7, Panel
B) and rate of FVa307-506 fragment (Figure 7, Panel D)
were both suppressed relative to reactions without pro-
thrombin (Figure 3 Panels D and E, respectively)
suggesting both sites were protected. At 20 nM APC
(Figure 7, Panel A, blue circles) the initial rate of FVaHC
proteolysis (520 pM/s) is similar to that observed with
2.0 nM APC in the absence of prothrombin (558 pM/s).Contrary to inactivation experiments in the absence of
prothrombin (Figure 3, Panel B), there is a more notice-
able generation of the FVa307-679/709 fragment (Figure 7,
Panel A inset) that enables more reliable densitometric
quantitation (Figure 7, Panel C).
Mathematical Simulations
An additional reaction describing the reversible forma-
tion of the FVa•PT complex with a KD of 700 nM [39]
was added to the ordinary differential equation (ODE)
network (Table 2, Eqn 17). The initial concentration of
Figure 8 Effect of Prothrombinase Components on APC
Proteolysis of FVa. Normalized densitometry data measuring the
disappearance of the FVaHC are from reactions containing 20 μM PC:
PS, 2.0 nM APC and 20 nM FVa (filled circles, N = 6), with either 30
nM active site blocked FXa (open circles, N = 5), 1.4 μM prothrombin
(filled triangles, N = 4), or 30 nM active site blocked FXa + 1.4 μM
prothrombin (open triangles, N = 4). Solid lines are fits of the
empirical data to monophasic exponential decay curves (FVa,
FVa + FXa*, and FVa + PT) or a linear decay (FVa + FXa* + PT).
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μM PT, was calculated to be 13.3 nM. Simulated time
courses for FVa heavy chain fragments generated by
APC (2.0 nM or 20.0 nM, red and blue lines, respect-
ively) proteolysis did not correlate well with the empir-
ical data, in fact suggesting that there would be little to
no protection of FVa by 1.4 μM prothrombin if the KD
was 700 nM (Figure 7, Panel A, dashed with dotted lines
vs. filled circles; Note, red dashed with dotted line is
underneath blue dashed line). Test simulations varying
the KD were performed by altering the koff constant for
the equilibrium describing the prothrombin and FVa
interaction. Even when a KD of 50 nM was assigned to
the interaction, ~ 10-fold less than published estimates
[40] the resulting simulations did not capture the
observed level of protection (data not shown).
In the computational model one of the assumptions is
the presence of unlimited binding sites located on a single
surface so that competition between proteins for occu-
pancy of the phospholipid surface is not a factor. At 20
μM PC:PS vesicles, and setting the phospholipid/protein
binding site ratio between 30 and 60 [59-61], available
binding sites fall in a range between 220 and 440 nM. The
simultaneous solution of the equilibrium expressions for
prothrombin, FVa, and APC (defined as non-catalytic)
binding to phospholipid membrane with KD’s of 230 nM
[62], 2.72 nM [63], and 500 nM [64], respectively, shows
that between 77–78 % of binding sites are occupied by
prothrombin, over 96 % of the FVa is bound, and only ap-
proximately 11 % of the APC is able to bind to the surface
whether 2.0 or 20.0 nM APC is present. By using this
bound fraction of APC as the catalytically relevant popula-
tion, the mathematical simulations better captured the
kinetics of FVHC proteolysis in the presence of 1.4 μM
prothrombin (Figure 7, Panel A, solid lines vs. filled cir-
cles). Similarly, comparison of empirical and simulated
time courses for the three generated fragments (Figure 7,
Panels B-D, filled circles vs. solid lines) also show
improved fits. Our findings indicate that there may in fact
be a tighter association between FVa and PT, in line with
the findings of Yegneswaran et al. (Figure 7. Panel A, filled
circles vs. dashed lines) [40].
To verify that the impaired FVa proteolysis observed
under the empirical reaction conditions was not solely
due to competition for phospholipid binding sites, math-
ematical simulations were constructed using the
adjusted APC concentration, but without permitting the
formation of the FVa•PT complex. This model construct
failed to predict the time courses for FVaHC disap-
pearance and the fragments FVa1-506 and FVa307-679/709
(Figure 7, Panel A, B and C, filled circles vs. dotted
lines). Thus the computational studies indicate that the
prothrombin dependent suppression of FVa proteolysis
by APC observed in our empirical reactions is due bothto binding site competition (prothrombin membrane as-
sociation limiting APC access to the membrane surface)
and to the FVa•PT complex not being a substrate for
APC. Comparisons of the empirical data for FVaHC pro-
teolysis (Figure 7, Panel A) with the simulations repre-
senting unlimited binding sites (dashed with dotted
lines), limited binding site adjustment but no FVa•PT
interaction (dotted line) and the limited binding site ad-
justment with FVa•PT complex formation (KD = 700 nM)
(solid line) indicate that under these conditions approxi-
mately half of the observed PT dependent suppression is
due to FVa•PT complex formation.
APC Inactivation of Factor Va: Effect of Prothrombin and
Saturating Levels of Factor Xa
Empirical Analysis
In order to measure the cumulative protection pro-
thrombin and saturating levels of active site blocked FXa
have on the APC inactivation of FVa, reactions were car-
ried out at physiological concentrations of FVa (20 nM)
and prothrombin (1.4 μM), with saturating levels of
FXa* (30 nM) on phospholipid vesicles (20 μM). Figure 8
summarizes the time course data for FVaHC proteolysis by
2.0 nM APC for reactions constructed with FVa, FVa+
FXa*, FVa+PT, and FVa+FXa*+PT. The combined pre-
sence of prothrombin and FXa* provided maximum pro-
tection against APC inactivation.
Figure 9 presents the empirical data comparing the
proteolysis of FVa in the presence of 30 nM FXa* and
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A shows a representative Western blot for the reactions
with 2.0 nM APC. Visual inspection of Western blots
revealed extremely low generation of the inactivation
fragments FVa1-506, FVa307-679/709, and FVa307-506. Pro-
ductions of these fragments were consistently barely
above detection limits and thus made measurement of
these fragments highly variable, and as a result were not
considered further.Figure 9 APC Inactivation of FVa in the Presence of
Prothrombin and Saturating Levels of FXa. Empirical: FVa (20 nM)
was pre-incubated with 30 nM active site blocked FXa (FXa*) and
prothrombin (1.4 μM) at 37°C. The reaction was initiated with 2.0 nM
(red circles) or 20.0 nM (blue circles) APC. A representative Western
blot from an empirical experiment using 2.0 nM APC is shown in
Panel A. Densitometric analysis of normalized measurements of the
FVaHC are presented in Panel B. Data points are the averages ± S.D.
of either 4 or 3 experiments for inactivation studies conducted with
either 2.0 or 20.0 nM APC, respectively. Mathematical: Simulated
time courses (2.0 nM APC – red lines; 20.0 nM APC – blue lines)
were generated with the assumption of limited binding sites,
resulting in an effective APC concentration of 11 % (solid line) is
shown.Addition of 2.0 nM APC to the reaction system led to
only 39 % of the FVaHC being proteolyzed after 20
minutes (Figure 9, Panel B, red circles). The initial rate
of disappearance was 14 pM/s, nearly 41-fold lower than
the inactivation rate in the absence of both prothrombin
and FXa (558 pM/s; Figure 3, Panel A, red circles). In-
activation studies with 10 times more APC resulted in a
nearly 8-fold increase in the initial rate of inactivation
(100 pM/s) (Figure 9, Panel B, blue circles).
Mathematical Simulations
To incorporate the formation of the ternary prothrombi-
nase•substrate complex, four additional reactions are
required (Table 3, Eqns 19–22). Based on studies indi-
cating that prothrombinase complexes formed with par-
tially proteolyzed FVa species have a KM similar to the
complex formed with intact FVa [31,51], we set the KM
of prothrombin for any prothrombinase complex to be
the same and consistent with previous modeling studies
[46,47]. We included two additional reactions (Table 3,
Eqns 23–24) to allow for the dissociation of the ternary
complex formed with some of the partially proteolyzed
FVa species. Solving the simultaneous equilibrium of
FVa, FXa*, and PT in a lipid independent system, ap-
proximately 18.9 nM FVa is found in a prothrombinase
complex (FVa•FXa or FVa•FXa•PT), approximately 720
pM FVa is in the FVa•PT complex, and approximately
360 pM FVa is unassociated.
Simulated time courses for the disappearance of the
FVaHC were generated for the experiments where 2.0
nM or 20.0 nM APC was added. Based on the findings
from the APC inactivation studies of FVa in the pres-
ence of prothrombin, APC effective concentrations were
adjusted to 11 % of the total to account for the limited
binding sites (Figure 9, Panel B, solid lines). The simula-
tions’ initial rates of proteolysis of the FVaHC (6 pM/s)
were less than half the measured empirical rates (14
pM/s). The mathematical simulations greater level of
protection extends through 20 minutes with higher
amounts of FVaHC anticipated compared to empirical
results (2.0 nM APC: 76 % vs. 61 %, respectively; 20.0
nM APC: 26 % vs. 11 %, respectively) (Figure 9, Panel
B). Empirical studies were also conducted with 50 μM
PC:PS vesicles and did not result in any significant
changes in the initial rate or overall time course of
FVaHC proteolysis by 2.0 nM APC (data not shown),
suggesting that under the current conditions, phospho-
lipid membrane accessibility is not impeding the inacti-
vation reaction.
Potential explanations for this disparity include: 1)
accumulated effect of small errors in rate constants; 2)
improved binding of APC to the surface; 3) a misesti-
mate of the affinity of the prothrombinase•prothrombin
interaction; and 4) the affinity of human APC for FVa is
Table 3 Equations describing interactions between catalytically inactive prothrombinase species and prothrombin
Eqn Chemical Expression koff kon kdis
(s-1) (M-1 s-1) (s-1)
19 FXa•FVa + PT 14-13! FXa•FVa•PT 103 a 1.0 x 108 a
20 FXa•FVai
506 + PT 14-13! FXa•FVai506•PT 103 1.0 x 108
21 FXa•FVai
306 + PT 14-13! FXa•FVai306•PT 103 1.0 x 108
22 FXa•FVai
306/506 + PT 14-13! FXa•FVai306/506•PT 103 1.0 x 108
23 FXa•FVai
306•PT −9! FXa + FVa1-306•FVaLC + FVa307-679/709 + PT 0.0035
24 FXa•FVai
306/506•PT −9! FXa + PT+ FVa1-306•FVaLC + FVa307-506 + FVa507-679/709 0.0035
a Values from previously published studies for mathematical simulations [32,46].
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experiments will be required to distinguish between
these possibilities. It is important to note that phospho-
lipid composition plays an important role in protein-
membrane interactions which can extend to effects on
enzyme activity (Reviewed in [65]). Several studies have
directly highlighted the effect of membrane composition
on the APC inactivation of FVa [66-68].
Conclusions
We have constructed an ODE based model of APC in-
activation of the prothrombinase complex. This model
includes 24 chemical reactions and interactions with 14
unique rate constants which describe the flux in concen-
trations of 24 species (Figure 10). We did so in stepwise
fashion, analyzing the time course of FVa inactivation in
empirical reaction systems with increasing number of
interacting components and generating corresponding
model constructs of each reaction system. Reaction
mechanisms, rate constants and equilibrium constants
informing these model constructs were initially derived
from various research groups reporting on APC inactiva-
tion of FVa in isolation [22,31-33], in the presence of
FXa [14,34-38], and in the presence of prothrombin
[39,40,58]. Model predictions were assessed against em-
pirical time course data measuring the appearance and
disappearance of multiple FVa degradation intermediates
as well as prothrombinase activity changes, with experi-
ments done multiple times, with plasma proteins derived
from multiple preparations. Current coagulation models
that incorporate the protein C pathway [69-79] provide
an often simplistic one step inactivation reaction of FVa
by APC, without incorporating the feedback inhibition
of the APC•FVa1-306•FVaLC complex, the ability of par-
tially proteolyzed FVa species to form catalytically active
prothrombinase species, and the formation of FVa•PT
species. They either do not provide empirical data verify-
ing their model construct or rely on a single global out-
put to validate the entire model construct. Wagenvoord
et al. have outlined the limitations of mathematical mod-
els of complex reaction networks validated by a single
analyte [80]. This study highlights the complexity of theinactivation process and is a crucial step towards creat-
ing a module of equations describing the PC pathway
that can be integrated into existing comprehensive
mathematical models describing the interplay between




Human prothrombin and Factor X were isolated accord-
ing to methods as described [81]. Factor Xa was prepared
as previously described using Russel’s Viper Venom Factor
Xa Activator [82,83]. Human Factor V was purified from
citrated plasma according to previously described proce-
dures [83]. Activated human protein C was purchased
from Haematologic Technologies, Essex Junction, VT. 1,2-
Dioleolyl-sn-Glycero-3-Phospho-L-Serine (PS) and 1,2-Dio-
leoyl-sn-Glycero-3-Phosphocholine (PC) were purchased
from Avanti Polar Lipids, Inc (Alabaster, AL) and phospho-
lipid vesicles (PC:PS) composed of 75 % PC and 25 % PS
were prepared as described [60,84]. Spectrozyme TH and
recombinant hirudin were purchased from American Diag-
nostica, Inc (Greenwich, CT) and EDTA was purchased
from Sigma (St Louis, MO). D-Phe-Pro-ArgCH2Cl (FPRck)
was prepared in house. Monoclonal anti-fV (αHFV#17)
was obtained from the Biochemistry Antibody Core La-
boratory (University of Vermont) and a goat anti-mouse
IgG conjugated to HRP was purchased from Southern Bio-
tech (Birmingham, AL). Active site blocked FXa (FXa*) was
produced according to the previously published method
[85].
Multiple preparations of FV/FVa and different lots of
APC were utilized for these studies. Preparations of Factor
Va were made fresh prior to all experiments. Factor V
(1.0 μM) in 0.2 M HEPES, 0.15 M NaCl, 0.1 % PEG-8000,
2.0 mM CaCl2, pH 7.4 (HBS-PEG-Ca) was activated with
10 nM human thrombin for 10 min at 37°C. Thrombin ac-
tivation was stopped by addition of 12 nM recombinant
hirudin and placing the sample on ice. Factor Va prepara-
tions were used within 4 hours. The partially proteolyzed
species of factor Va cleaved only at Arg506 was generated
by incubating FVa (750 nM) in HBS-PEG-Ca with 5.0 nM
Figure 10 Reaction Scheme of APC Inactivation of FVa in the Presence of Either FXa or Prothrombin. Schematic of reactions and
interactions involved in the APC inactivation of FVa when in the presence of either FXa (highlighted in blue and red) or prothrombin (highlighted
in green). The interaction highlighted in red was identified in this study through the validation of the mathematical model describing the APC
inactivation of FVa. Formation of the prothrombinase plus prothrombin species (Table 3, Eqns 19–22) and their dissociation (Table 3, Eqns 23–24)
are not shown in this figure for clarity.
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5.0 nM APC was added. Following the inactivation reac-
tion, the FVai
506 containing reaction was placed on ice and
incubated with 1.0 mM di-isopropyl phosphate to inacti-
vate the APC.
Inactivation of Factor Va by Activated Protein C
Solutions of factor Va (20 nM) in HBS-PEG-Ca with
20 μM PC:PS were prepared at 37°C. At the zero time
point 0.5 or 2.0 nM APC was added to the FVa solution.
At designated intervals samples were removed, and ei-
ther quenched in denaturing sample preparation buffer
(0.31 M Tris[hydroxymethyl]aminomethane, 10 % so-
dium dodecyl sulfate, 50 % glycerol, 0.5 % Bromophenol
Blue, pH 6.8) and analyzed either for proteolytic cleavage
using SDS-PAGE and subsequent immunoblot analysis
(Western blotting), or for co-factor activity using a one-
stage clotting assay in factor V deficient plasma. Inacti-
vation reactions were diluted 40-fold in an appropriate
volume of factor V deficient plasma and assayed imme-
diately. Clotting activity is represented as a percentage of
the clotting time observed for unproteolyzed FVa.
Inactivation of Factor Va by Activated Protein C in the
Presence of Factor Xa
Activity analysis:
Rates of APC inactivation of FVa (0.2 nM) in the presence
of PC:PS vesicles (20 μM) and FXa (0.1 nM) were assessed
with the prothrombinase complex preformed for five min-
utes at 37°C in HBS-PEG-Ca. At the zero time point APC
(0–2.0 nM) was added to the prothrombinase complex so-
lution. At designated intervals aliquots were removed and
added to a minimal amount of concentrated prothrombin
(1.0 μM final). After 90 s, aliquots were quenched with the
addition of 0.5 M EDTA (25 mM final) and subsequently
monitored for thrombin activity against the chromogenicsubstrate SpecTH. Thrombin concentrations were deter-
mined by reference to a standard curve and the level of
thrombin generated used as a relative measurement of
prothrombinase concentration compared to measure-
ments with intact FVa.
Proteolytic analysis:
Prothrombinase complex was preformed on 20 μM PC:
PS vesicles in HBS-PEG-Ca for four minutes at 37°C
using 30 nM fluorescein-active site blocked FXa (FXa*)
and 20 nM FVa. A sample aliquot was removed, APC
added (2.0 nM), aliquots taken at selected time points
and quenched into denaturing sample preparation buffer,
and subsequently analyzed by Western blotting.
Inactivation of Factor Va by Activated Protein C in the
Presence of Prothrombin
Reaction mixtures of FVa (20 nM) and prothrombin
(1.4 μM) were prepared with 20 μM PC:PS vesicles in
HBS-PEG-Ca and incubated for four minutes at 37°C. A
sample aliquot was removed, APC added (2.0 or 20.0 nM),
aliquots taken at selected time points and quenched into
denaturing sample preparation buffer, and subsequently
analyzed by Western blotting.
Inactivation of Factor Va by Activated Protein C in the
Presence of Prothrombin and Factor Xa
Reaction mixtures of FVa (20 nM), fluorescein-active site
blocked FXa (FXa*, 30 nM), and prothrombin (1.4 μM)
were prepared with 20 μM PC:PS vesicles in HBS-PEG-Ca
and incubated for four minutes at 37°C. A sample aliquot
was removed, APC added (2.0 or 20.0 nM), aliquots taken
at selected time points and quenched into denaturing sam-
ple preparation buffer, and subsequently analyzed by
Western blotting.
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All FVa samples were run under reducing conditions. FVa
heavy chain and inactivation fragments were analyzed by
fractionation on 4-12 % SDS-PAGE acrylamide slab gels
followed by electrophoretic transfer of proteins to Immo-
bilon-FL membranes (Millipore Inc., Billerica, MA), and
detected using a mouse monoclonal antibody (αHFV#17)
that binds to an epitope between residues 307–506 of the
factor Va heavy chain and a goat anti-mouse IgG con-
jugated to HRP (Southern Biotech). Luminescence was
detected using a Fuji LAS-4000 in conjunction with Ima-
geCapture software (Fujifilm, Tokyo, Japan). Densitometry
was carried out using MultiGauge software (Fujifilm,
Tokyo, Japan). For each species, densitometric values at
each time point were normalized to their maximal value
during the time course.Mathematical modeling
The description using ordinary differential equations of
the reaction pathway for bovine APC inactivation of
bovine FVa reported by Hockin et al. [33] was used as a
starting framework (Figure 2; Table 1). The scheme
describes a random order cleavage process for Arg306
and Arg506 in which the cleavages are independent of
each other and characterized by substantially different
rate constants. Our simulator employs a fourth order
Runga-Kutta algorithm to generate a series of time-
dependent concentration profiles for all reactants, inter-
mediates, and products.
Factor Va cofactor activity will be represented by the
cumulative presence of FVaHC species present at any
point in time. For measurements of prothrombinase ac-
tivity, the sum of all FVa species was added to the




Factor Va inactivation fragments will be represented by
including respective fragments both associated and dis-
sociated from the FVaLC.
To generate an appropriate simulation of the empirical
experiment where FXa and FVa are pre-incubated together
on the phospholipid surface to form the prothrombinase
complex prior to the addition of APC, the concentrations
of free FXa and FVa, and the prothrombinase complex were
solved. For example, studies with 200 pM FVa and 100 pM
FXa, for each potential KD (e.g. 0.1 nM or 0.5 nM, respect-
ively), the values of the three initial conditions ranged from
41–74 pM for free FXa, 141–174 pM for free FVa, and 59–
26 pM for prothrombinase. The concentrations of the three
species then served as the initial conditions in the simula-
tions in conjunction with either APC concentration.
In silico simulations were carried out with the initial
concentrations used in the empirical experiments and the
relevant output calculated and compared to the appropri-
ate analyte measured in the empirical experiments.Abbreviations
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